Sign In
Last checked at 
10 Nov 2025 07:00
10 November 2025
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
PDMR Dealing / Grant of Share Options
Oxford BioDynamics Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch® 3D genomics platform, announces that it has today granted a total of 170,000,000 options over its ordinary shares of 0.1 pence each ("Ordinary Shares"), to Group employees and advisers, including certain directors and PDMRs of the Company, as outlined in the table below.
The options were granted under the Company's 2016 Employee and Non-Employee Share Option Plans with an exercise price of 0.61p per share, representing a premium of 100% over the closing share price on 7 November 2025, the business day immediately preceding the grant of the options.
119,000,000 options granted to directors and PDMRs will vest monthly in 24 equal tranches to 10 November 2027.
51,000,000 options will vest in three tranches: 20% will vest immediately and will be exercisable from six months after the date of grant; 40% will vest and become exercisable on 10 November 2026; and 40% will vest and become exercisable on 10 November 2027.
Vested options will remain exercisable up to and including the tenth anniversary of the date of grant.
The grants made to directors and PDMRs of the Company were as follows:
New options granted | Total number of options over Ordinary Shares | Ordinary Shares held* | ||
Number | % of current issued share capital | |||
Iain Ross, Executive Chairman | 44,000,000 | 140,000,000 | 23,333,333 | 0.54 |
Alexandre Akoulitchev, Chief Scientific Officer | 15,000,000 | 34,596,131 | 14,228,962 | 0.33 |
David Blum, SVP of Marketing | 15,000,000 | 33,462,500 | 744,611 | 0.02 |
Thomas Guiel, Chief Operations Officer | 15,000,000 | 33,650,000 | 6,288,146 | 0.15 |
Ewan Hunter, Chief Data Officer | 15,000,000 | 33,660,000 | 722,754 | 0.02 |
Paul Stockdale, Chief Financial Officer | 15,000,000 | 33,980,000 | 6,411,252 | 0.15 |
*Shareholdings are stated following allotments pursuant to the recent fundraising. Percentages are calculated with reference to the Company's Enlarged Share Capital following General Admission, which is expected to take place on 11 November 2025.
The notifications below, made in accordance with the requirements of UK Market Abuse Regulation, provide further details:
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Alexandre Akoulitchev |
2 | Reason for the notification | |
a) | Position/status | Director/PDMR |
b) | Initial notification/ Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Oxford BioDynamics Plc |
b) | LEI | 2138005Y1TK258O5U928 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 0.1 pence each
ISIN: GB00BD5H8572 |
b) | Nature of the transaction | Grant of share options |
c) | Price(s) and volume(s) | 15,000,000 ordinary shares at an exercise price of 0.61 pence per share
|
d) | Aggregated information - Aggregated volume - Price
| N/A
|
e) | Date of the transaction | 10 November 2025
|
f) | Place of the transaction | Outside a trading venue |
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | David Blum |
2 | Reason for the notification | |
a) | Position/status | PDMR |
b) | Initial notification/ Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Oxford BioDynamics Plc |
b) | LEI | 2138005Y1TK258O5U928 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 0.1 pence each
ISIN: GB00BD5H8572 |
b) | Nature of the transaction | Grant of share options |
c) | Price(s) and volume(s) | 15,000,000 ordinary shares at an exercise price of 0.61 pence per share
|
d) | Aggregated information - Aggregated volume - Price
| N/A
|
e) | Date of the transaction | 10 November 2025
|
f) | Place of the transaction | Outside a trading venue |
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Thomas Guiel |
2 | Reason for the notification | |
a) | Position/status | PDMR |
b) | Initial notification/ Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Oxford BioDynamics Plc |
b) | LEI | 2138005Y1TK258O5U928 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 0.1 pence each
ISIN: GB00BD5H8572 |
b) | Nature of the transaction | Grant of share options |
c) | Price(s) and volume(s) | 15,000,000 ordinary shares at an exercise price of 0.61 pence per share
|
d) | Aggregated information - Aggregated volume - Price
| N/A
|
e) | Date of the transaction | 10 November 2025
|
f) | Place of the transaction | Outside a trading venue |
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Ewan Hunter |
2 | Reason for the notification | |
a) | Position/status | PDMR |
b) | Initial notification/ Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Oxford BioDynamics Plc |
b) | LEI | 2138005Y1TK258O5U928 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 0.1 pence each
ISIN: GB00BD5H8572 |
b) | Nature of the transaction | Grant of share options |
c) | Price(s) and volume(s) | 15,000,000 ordinary shares at an exercise price of 0.61 pence per share
|
d) | Aggregated information - Aggregated volume - Price
| N/A
|
e) | Date of the transaction | 10 November 2025
|
f) | Place of the transaction | Outside a trading venue |
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Iain Ross |
2 | Reason for the notification | |
a) | Position/status | Director/PDMR |
b) | Initial notification/ Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Oxford BioDynamics Plc |
b) | LEI | 2138005Y1TK258O5U928 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 0.1 pence each
ISIN: GB00BD5H8572 |
b) | Nature of the transaction | Grant of share options |
c) | Price(s) and volume(s) | 44,000,000 ordinary shares at an exercise price of 0.61 pence per share
|
d) | Aggregated information - Aggregated volume - Price
| N/A
|
e) | Date of the transaction | 10 November 2025
|
f) | Place of the transaction | Outside a trading venue |
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Paul Stockdale |
2 | Reason for the notification | |
a) | Position/status | Director/PDMR |
b) | Initial notification/ Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Oxford BioDynamics Plc |
b) | LEI | 2138005Y1TK258O5U928 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 0.1 pence each
ISIN: GB00BD5H8572 |
b) | Nature of the transaction | Grant of share options |
c) | Price(s) and volume(s) | 15,000,000 ordinary shares at an exercise price of 0.61 pence per share
|
d) | Aggregated information - Aggregated volume - Price
| N/A
|
e) | Dates of the transactions | 10 November 2025
|
f) | Place of the transaction | Outside a trading venue |
-Ends-
For further details please contact:
Oxford BioDynamics Plc | Tel: +44 (0)1865 518910 |
Iain Ross, Executive Chairman Paul Stockdale, CFO | |
Shore Capital - Nominated Adviser and Broker | Tel: +44 (0)20 7408 4090 |
Stephane Auton / Lucy Bowden | |
OAK Securities - Joint Broker | Tel: +44 (0)20 3973 3678 |
Matthew Clarke / Tim Dainton / Calvin Man | |
Camarco - Financial PR | Tel: +44 (0)20 3757 4980 |
Marc Cohen / Tilly Butcher / Fergus Young | OBDFinancial@camarco.co.uk |
Notes to Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.
Currently OBD has two commercially available products: the EpiSwitch® PSE (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.
The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch® which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.
OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.
The Group's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.
OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, www.oxfordbiodynamics.com, X (@OxBioDynamics) or LinkedIn.
Follow the stocks
